Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva

A composition comprising:

• a pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including:
• 2% w/w to 20% w/w melatonin in a therapeutically effective amount;
• a carrier matrix including 45% w/w to 68% w/w filler, 6% w/w to 20% w/w disintegrant, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva;
• and
• 20% w/w to 30% w/w acid, the amount of acid being effective to impart the pH to the saliva, wherein the dosage form is at least one of a sublingual tablet and a buccal tablet.